Hepatoselüler kanserli hastalarda lokal bölgesel tedaviler ve sorafenib kombinasyonun etkinlik ve güvenilirliği: Tek merkez deneyimi

Harun Muğlu; Erdem Sünger; Mehmet Haluk Yücel; Maral Martin Mıldanoğlu; Ebru Engin Delipoyraz; Jamshid Hamdard; Hakan Özçelik; Özgür Açıkgöz; Ahmet Bilici; Ebru Karcı; Omer Fatih Olmez; Özcan Yıldız; Cengiz Erol

doi:10.19161/etd.1569835

EN TR

Efficacy and safety of combined locoregional therapy and sorafenib in hepatocellular carcinoma: Single center experience

Abstract

Aim: Hepatocellular carcinoma represents a significant global health concern, with a substantial proportion of patients presenting at an unresectable stage. Locoregional therapies and systemic agents such as sorafenib have emerged as pivotal modalities in the management of Hepatocellular carcinoma. This retrospective study aimed to evaluate the efficacy and safety of combining Locoregional therapies with sorafenib in patients diagnosed with Hepatocellular carcinoma. Materials and Methods: A cohort of 20 Hepatocellular carcinoma patients followed at Medipol Mega University Hospital between 2018 and 2023 was retrospectively analyzed. All patients underwent Locoregional therapies in conjunction with sorafenib treatment. Progression free survival and overall survival rates, adverse events, and prognostic factors were assessed. Results: Upon receiving combination therapy, an objective response rate of 90% and a disease control rate of 95% were observed. Median progression free survival was determined to be 11,1 months, while median overall survival was 18,6 months. Multivariate analysis revealed that Locoregional therapies type and transplantation status were independent prognostic indicators for progression free survival, whereas ECOG performance status was an independent prognostic factor for overall survival. Dermatological adverse events were the most frequently reported. Conclusion: Our findings suggest that the concurrent administration of Locoregional therapies and sorafenib may offer a safe and effective therapeutic strategy for patients with Hepatocellular carcinoma. This combined approach has the potential to prolong progression free survival and overall survival. However, to definitively establish the clinical benefits of this regimen, larger scale, prospective trials are warranted.

Keywords

Hepatoselüler kanserli hastalarda lokal bölgesel tedaviler ve sorafenib kombinasyonun etkinlik ve güvenilirliği: Tek merkez deneyimi

Öz

Amaç: Hepatoselüler karsinom, dünya genelinde önemli bir sağlık sorunu olan bir karaciğer kanseridir. Çoğu hasta unrezektabl evrede tanı alır. Lokal bölgesel tedaviler ve sorafenib gibi sistemik tedaviler, Hepatoselüler kanser tedavisinde kullanılan önemli yöntemlerdir. Bu çalışmada, Lokal bölgesel tedaviler ve sorafenib kombinasyonunun Hepatoselüler kanser hastalarındaki etkinliği ve güvenilirliği retrospektif olarak araştırılmıştır. Gereç ve Yöntem: 2018 2023 yılları arasında Medipol Mega Üniversite Hastanesi’nde takip edilen 20 Hepatoselüler kanser tanılı hasta çalışmaya dahil edildi. Hastaların tümüne Lokal bölgesel tedaviler ve sorafenib tedavisi uygulandı. Progresyonsuz sağkalım ve genel sağkalım süreleri, yan etkiler ve prognostik faktörler değerlendirildi. Bulgular: Kombinasyon tedavi sonrası objektif yanıt oranı %90, hastalık kontrol oranı %95 olarak bulundu. Ortanca progresyonsuz sağkalım 11,1 ay, ortanca genel sağkalım 18,6 ay olarak saptandı. Çok değişkenli analizde, progresyonsuz sağkalım için lokal bölgesel tedavi tipi ve nakil varlığı, genel sağkalım için ise ECOG performans durumu bağımsız prognostik faktörler olarak belirlendi. En sık görülen yan etki dermatolojik yan etkiler oldu. Sonuç: Çalışmamız, Hepatoselüler Kanser hastalarında Lokal bölgesel tedaviler ve sorafenib kombinasyonunun güvenli ve etkili olabileceğini göstermektedir. Bu kombinasyon, progresyonsuz sağkalım ve genel sağkalım sürelerini uzatabilir. Ancak, bu konuda daha büyük, prospektif çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

Kaynakça

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer, 2010;127(12):2893-917.
Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology, 2015;61(1):191-9.
Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatology international, 2019;13:125- 37.
Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. The Lancet, 2002;359(9319):1734-9.
Riaz A, Gates VL, Atassi B, Lewandowski RJ, Mulcahy MF, Ryu RK, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. International Journal of Radiation Oncology* Biology* Physics, 2011;79(1):163-71.
Ozkan ZG, Poyanli A, Ucar A, Kuyumcu S, Akyuz F, Keskin S, et al. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis. Cancer Biotherapy and Radiopharmaceuticals, 2015;30(3):132-8.
Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 1: technical and methodologic considerations. Journal of vascular and interventional radiology, 2006;17(8):1251-78.
Niu G, Chen X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Current drug targets, 2010;11(8):1000-17.

Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. Journal of clinical oncology, 2011;29(29):3892-9.
Zhang W, Kim R, Quintini C, Hashimoto K, Fujiki M, Diago T, et al. Prognostic role of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma undergoing liver transplantation. Liver Transplantation, 2015;21(1):101-11.
Labeur TA, Ten Cate DW, Bart Takkenberg R, Azahaf H, van Oijen MG, van Delden OM, et al. Are we SHARP enough? The importance of adequate patient selection in sorafenib treatment for hepatocellular carcinoma. Acta Oncologica, 2018;57(11):1467-74.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. New England journal of medicine, 2008;359(4):378-90.
Dufour J-F, Hoppe H, Heim MH, Helbling B, Maurhofer O, Szucs-Farkas Z, et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. The oncologist, 2010;15(11):1198-204.
Chung YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, et al. Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. International journal of cancer, 2013;132(10):2448-58.
Erhardt A, Kolligs F, Dollinger M, Schott E, Wege H, Bitzer M, et al. TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. Cancer chemotherapy and pharmacology, 2014;74:947-54.
Shim JH, Park JW, Kim JH, An M, Kong SY, Nam BH, et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer science, 2008;99(10):2037-44.
Park J-W, Koh YH, Kim HB, Kim HY, An S, Choi J-I, et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. Journal of hepatology, 2012;56(6):1336-42.
Kudo M, Imanaka K, Chida N, Nakachi K, Tak W-Y, Takayama T, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. European journal of cancer, 2011;47(14):2117-27.
Gadaleta C, Mattioli V, Colucci G, Cramarossa A, Lorusso V, Canniello E, et al. Radiofrequency ablation of 40 lung neoplasms: preliminary results. American journal of roentgenology, 2004;183(2):361-8.
Gadaleta CD, Solbiati L, Mattioli V, Rubini G, Fazio V, Goffredo V, et al. Unresectable lung malignancy: combination therapy with segmental pulmonary arterial chemoembolization with drug-eluting microspheres and radiofrequency ablation in 17 patients. Radiology, 2013;267(2):627-37.

Ayrıntılar

Birincil Dil

Türkçe

Konular

Katı Tümörler

Bölüm

Araştırma Makalesi

Yazarlar

Harun Muğlu ^*
0000-0001-9584-0827
Türkiye

Erdem Sünger
0000-0001-5194-1634
Türkiye

Mehmet Haluk Yücel
0000-0001-6880-7204
Türkiye

Maral Martin Mıldanoğlu
0000-0002-4587-0726
Türkiye

Ebru Engin Delipoyraz
0000-0003-4979-3630
Türkiye

Jamshid Hamdard
0000-0002-5823-1704
Türkiye

Hakan Özçelik
0009-0009-4967-6611
Türkiye

Özgür Açıkgöz
0000-0003-2715-4002
Türkiye

Ahmet Bilici
0000-0002-0443-6966
Türkiye

Ebru Karcı
0000-0001-8802-6376
Türkiye

Omer Fatih Olmez
0000-0001-7934-7039
Türkiye

Özcan Yıldız
0000-0003-4345-7599
Türkiye

Cengiz Erol
0000-0003-3468-7712
Türkiye

Yayımlanma Tarihi

12 Mart 2025

Gönderilme Tarihi

18 Ekim 2024

Kabul Tarihi

20 Kasım 2024

Yayımlandığı Sayı

Yıl 2025 Cilt: 64 Sayı: 1

DOI

https://doi.org/10.19161/etd.1569835

IZ

https://izlik.org/JA46XT62GC

Kaynak Göster

RIS / Bibtex

Vancouver

1.Harun Muğlu, Erdem Sünger, Mehmet Haluk Yücel, Maral Martin Mıldanoğlu, Ebru Engin Delipoyraz, Jamshid Hamdard, Hakan Özçelik, Özgür Açıkgöz, Ahmet Bilici, Ebru Karcı, Omer Fatih Olmez, Özcan Yıldız, Cengiz Erol. Hepatoselüler kanserli hastalarda lokal bölgesel tedaviler ve sorafenib kombinasyonun etkinlik ve güvenilirliği: Tek merkez deneyimi. ETD. 01 Mart 2025;64(1):71-6. doi:10.19161/etd.1569835